LAist is part of Southern California Public Radio (SCPR), a member-supported public media network. Hear our news on-air at our partner site:
This is an archival story that predates current editorial management.
This archival content was written, edited, and published prior to LAist's acquisition by its current owner, Southern California Public Radio ("SCPR"). Content, such as language choice and subject matter, in archival articles therefore may not align with SCPR's current editorial standards. To learn more about those standards and why we make this distinction, please click here.
In the largest ever multi-state consumer protection-based pharmaceutical settlement, California will receive $5.6 million--the largest share of the $62 Million, 32 state settlement--from medicine maker Eli Lilly and Company, the makers of antipsychotic drug Zyprexa. “Eli Lilly put profits ahead of patients when it marketed Zyprexa for a use that had not been properly tested or approved, in many cases, putting young women at risk for weight gain, hypoglycemia and even diabetes,” Attorney General Brown said a statement released today. Eli Lilly was accused of engaging "in unfair and deceptive practices when it marketed Zyprexa for off-label uses and [failing] to adequately disclose the drug’s potential side effects to healthcare providers."